Clinical trials for neuroprotection in ALS

S Piazza, S Ruggieri - … (Formerly Current Drug Targets-CNS & …, 2010 - ingentaconnect.com
Owing to uncertainty on the pathogenic mechanisms underlying motor neuron degeneration
in amyotrophic lateral sclerosis (ALS) riluzole remains the only available therapy, with only …
被引用次数：54 相关文章

Clinical trials for neuroprotection in ALS.

G Siciliano, C Carlesi, L Pasquali, S Piazza… - CNS & Neurological …, 2010 - europepmc.org
Owing to uncertainty on the pathogenic mechanisms underlying motor neuron degeneration
in amyotrophic lateral sclerosis (ALS) riluzole remains the only available therapy, with only …

Clinical trials for neuroprotection in ALS

G Siciliano, C Carlesi, L Pasquali… - CNS & …, 2010 - pubmed.ncbi.nlm.nih.gov
Owing to uncertainty on the pathogenic mechanisms underlying motor neuron degeneration
in amyotrophic lateral sclerosis (ALS) riluzole remains the only available therapy, with only …

Clinical trials for neuroprotection in ALS

G Siciliano, C Carlesi, L Pasquali, S Piazza… - CNS & …, 2010 - iris.uniroma1.it
Owing to uncertainty on the pathogenic mechanisms underlying motor neuron degeneration
in amyotrophic lateral sclerosis (ALS) riluzole remains the only available therapy, with only …

Clinical Trials for Neuroprotection in ALS

G Siciliano, C Carlesi, L Pasquali, S Piazza… - CNS & …, 2010 - arpi.unipi.it
Owing to uncertainty on the pathogenic mechanisms underlying motor neuron degeneration
in amyotrophic lateral sclerosis (ALS) riluzole remains the only available therapy, with only …

[引用][C] Clinical Trials for Neuroprotection in ALS

G Siciliano, C Carlesi, L Pasquali, S Piazza… - CNS & Neurological …, 2010 - cir.nii.ac.jp

[引用][C] Clinical Trials for Neuroprotection in ALS

G SICILIANO, C CARLESI… - CNS & …, 2010 - Bentham Science Publishers